{
    "2021-10-15": [
        [
            {
                "time": "",
                "original_text": "万一下针的抗癌药物刷屏，公司有没有相关的研究方向？贝达药业：会积极关注该领域的發展情況",
                "features": {
                    "keywords": [
                        "抗癌药物",
                        "贝达药业",
                        "研究方向",
                        "关注",
                        "领域"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：目前广东集采征求意见稿纳入了埃克替尼，公司正在积极申诉反馈关于征求意见稿的相关问题。埃克替尼已申报参加今年医保谈判，并已通过核查",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "广东集采",
                        "埃克替尼",
                        "医保谈判",
                        "核查"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}